RankAlpha logo
Back to Rankings

TEVA

Teva Pharmaceutical IndustriesB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The strongest bull argument is that Q1 2026 showed branded growth carrying the model: AUSTEDO, AJOVY, and UZEDY collectively grew 41% in local currency, 2026 revenue guidance was maintained, and Teva reiterated 2027 margin and savings ambitions while layering in additional neuroscience optionality through Emalex. [#SEC-8K-2026-04-29]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.4.
What can break
Commercial execution risk remains elevated because higher selling and marketing expense was needed to support key innovative products, so revenue growth must continue to justify the spend. [#SEC-8K-2026-04-29]
Momentum
48
Value
65
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $39.80 · Bull $44.00 · Bear $28.00Analysis 2026-06-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $43.56
Why
Momentum48 · Δ7d -3.8
Value65 · Δ7d -0.0
Sentiment68 · Δ7d +4.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +4.4.

Contradictions & invalidation

  • • Commercial execution risk remains elevated because higher selling and marketing expense was needed to support key innovative products, so revenue growth must continue to justify the spend. [#SEC-8K-2026-04-29]
  • • Emalex adds integration, approval, and margin-risk complexity; Teva explicitly said the deal is expected to be near-term margin dilutive and is still subject to regulatory approvals. [#SEC-8K-2026-04-29]
  • • The bear case is that generic erosion, especially lenalidomide pressure, can keep offsetting branded momentum, while Emalex adds execution and near-term dilution risk before ecopipam contributes revenue; the company is improving, but the thesis still depends on several pipeline and launch milestones landing on time.

Catalyst clock

2026-06-30

Olanzapine LAI regulatory progress could sharpen the late-2026 launch setup

Lead driver: Sentiment · See AI snapshot
Momentum
48
9% active weight
Current posture
7d trendImproving
Δ7d
-3.8
Δ21d
-26.6
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.1
Sentiment
68
62% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+1.4
Why this grade

Composite grade B. Momentum 48.3 / Value 64.8 / Sentiment 67.8

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-11. Scenario method

B+
Bull case
30%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$39.80
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$42.43B
Beta
0.84
Shares Out
1.17B
P/E (TTM)
49.7
P/S (TTM)
2.08
P/FCF (TTM)
60.34
Rev YoY
-1.8%
EPS YoY
-302.7%
Gross Margin
+52.5%
Op Margin
+18.8%
Net Debt
$13.67B
Current Ratio
0.88
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data